Evaluation of HDAC8 as a Druggable Target in STAG2 -Mutant Ewing Sarcoma
ACS Chemical Biology · 2026
DOI: 10.1021/acschembio.6c00345 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Biology, 2026. Verfasst von Olasunkanmi Olaoye und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, …. Hauptthemen laut MEDLINE: Histone Deacetylases, Repressor Proteins, Sarcoma, Ewing, Antigens, Nuclear. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, American Cancer Society, National Cancer Institute.
Abstract (Originalsprache)
Ewing sarcoma is an aggressive pediatric cancer for which no targeted therapies have been approved. This disease is driven by EWSR1::ETS family fusions that, like most fusion transcription factors, have proven difficult to target directly. Here, we focus on identifying actionable dependencies within the high-risk STAG2-mutant (STAG2-mut) disease subtype of Ewing sarcoma. In STAG2-mut Ewing sarcoma, STAG1 knockout is synthetically lethal but is not readily druggable. Using the Cancer Dependency Map (DepMap), we identify histone deacetylase 8 (HDAC8) as an enriched vulnerability in this molecular context. CRISPR validation and a newly developed HDAC8 degrader, XY-09-36, confirm this selective dependency and suggest increased reliance on HDAC8-mediated cohesin regulation when STAG2 is lost. These findings establish HDAC8 as a context-dependent, pharmacologically accessible vulnerability and outline a framework for discovering rational targets in tumor subtypes where primary drivers are intrinsically hard to drug.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA02215, USA.
- Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA02215, USA.
- Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA02115, USA.
- Broad Institute of MIT and Harvard , Cambridge, MA02142, USA.
ORCID-Profile: Olasunkanmi Olaoye, Yuan Xiong, Radosław P Nowak, Eric S Fischer
Förderung
- NCI NIH HHS
- American Cancer Society
- National Cancer Institute
- National Institutes of Health (NIH)
- Elsa Pardee Foundation
- Lubin Family Foundation Fellowship Award
Zitieren
APA
Olaoye, O., Xiong, Y., Rillahan, C. D., Adane, B., DiGiovanni, G., Ross, K. N., Alexe, G., Howard, B., Kirmani, N., Nowak, R. P., Donovan, K. A., Fischer, E. S., & Stegmaier, K. (2026). Evaluation of HDAC8 as a Druggable Target in STAG2 -Mutant Ewing Sarcoma. ACS Chemical Biology. https://doi.org/10.1021/acschembio.6c00345
Vancouver
Olaoye O, Xiong Y, Rillahan CD, Adane B, DiGiovanni G, Ross KN, et al. Evaluation of HDAC8 as a Druggable Target in STAG2 -Mutant Ewing Sarcoma. ACS Chemical Biology. 2026. doi:10.1021/acschembio.6c00345
BibTeX
@article{Olaoye2026,
author = {Olaoye, Olasunkanmi and Xiong, Yuan and Rillahan, Cory D and Adane, Biniam and DiGiovanni, Giulia and Ross, Kenneth N and Alexe, Gabriela and Howard, Briana and Kirmani, Nadia and Nowak, Radosław P and Donovan, Katherine A and Fischer, Eric S and Stegmaier, Kimberly},
title = {Evaluation of HDAC8 as a Druggable Target in STAG2 -Mutant Ewing Sarcoma},
journal = {ACS Chemical Biology},
year = {2026},
doi = {10.1021/acschembio.6c00345}
}
EUVIMED